Stockreport

KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder

KemPharm, Inc.  (KMPH) 
Last kempharm, inc. earnings: 2/28 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.kempharm.com/investor-overview
PDF KP879 is being developed with serdexmethylphenidate, KemPharm’s prodrug of d-methylphenidate, to address a critical unmet need in the treatment of problematic stimulant [Read more]